Phase 2 Stomach Cancer Trial, Recruiting NCT05319639 Sponsor: Fujian Cancer Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT05319639
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with advanced, inoperable stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by tissue testing as a type called adenocarcinoma.
  • People whose cancer may or may not have clearly measurable tumours on scans.
  • People who are generally well enough to carry out light activity and care for themselves, as measured by a standard health performance scale (ECOG score of 0 or 1).
  • People whose blood, liver, and kidney test results fall within acceptable ranges set by the trial, without needing a blood transfusion in the 14 days before testing (confirm specific values with trial site).
  • People with a life expectancy of at least 3 months.
  • People with a normal heart tracing (ECG) and no history of heart failure.
  • People with normal blood clotting test results within the ranges specified by the trial.
  • Women of childbearing age who agree to use contraception starting 1 week before the first dose of the study drug and continuing until 8 weeks after the last dose.
  • Men who agree to use contraception throughout the study and for 8 weeks after the last dose.
  • People who are willing to sign a consent form and agree to attend follow-up appointments.
  • People who are willing and able to follow the study schedule and procedures.

Who may not be able to join:

  • People who have had another cancer diagnosis within the past 3 years, except for certain skin cancers, early-stage cervical changes, or non-spreading prostate cancer.
  • People whose cancer has spread to the brain or spinal fluid.
  • People who are pregnant or breastfeeding.
  • People with a serious wound, ulcer, or bone fracture that has not healed.
  • People with significant heart conditions, such as unstable chest pain, moderate-to-severe heart failure, or a heart attack within the past 6 months.
  • People who have had a stroke within the past 6 months.
  • People with significant problems with blood circulation in their limbs.
  • People who are unable to follow the study procedures or attend follow-up visits.
  • People who, in the treating doctor's opinion, are not stable enough to safely take part in a clinical trial for any other medical reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13705919382

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Fujian Cancer Hospital
Registry
ClinicalTrials.gov
Start date
16 February 2023
Est. completion
31 October 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The maximum dose tolerated

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov